Duloxetine plasma concentrations and its effectiveness in the treatment of nonorganic chronic pain in the orofacial region.
Duloxetine plasma concentrations and its effectiveness in the treatment of nonorganic chronic pain in the orofacial region.
复制标题
度洛西汀血浆浓度及其治疗口面部非器质性慢性疼痛的有效性。
DOI：
10.1097/wnf.0000000000000225
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Ozaki N.
中科院分区：
文献类型：
--
作者：
・Kobayashi Y;Nagashima W;Tokura T;Yoshida K;Umemura E;Miyauchi T;Arao M;Ito M;Kimura H;Kurita K;Ozaki N.
本研究的目的是探讨度洛沙酮的缓解疼痛的效果和其血浆浓度之间的关系，在orofacial region.MethodsWe的特点是慢性非器质性疼痛的患者灼口综合征和非典型性牙痛，度洛沙酮给77例诊断为有灼口综合征或非典型性牙痛12周。度洛沙汀的初始剂量确定为20 mg/d，第2周后增加至40 mg/d。在第0、2、4、6、8、10周，我们使用视觉模拟量表评估疼痛，使用汉密尔顿抑郁评定量表的结构化访谈指南评估抑郁症状，结果视觉模拟量表评分在12周后显著低于度洛沙汀给药开始时配对t检验，t= 6.65，P< 0.0001。我们检查了视觉模拟量表评分降低率与度洛沙汀血浆浓度之间的关系。有没有显着的线性回归或二次regression. ConclusionsDuloxastine显着缓解疼痛的慢性非器质性疼痛患者在orofacial区域。然而，没有观察到其镇痛作用与血药浓度之间的关系。
ObjectiveThe purpose of this study was to examine the relationship between the pain-relieving effects of duloxetine and its plasma concentrations in patients with burning mouth syndrome and atypical odontalgia characterized by chronic nonorganic pain in the orofacial region.MethodsWe administered duloxetine to 77 patients diagnosed as having burning mouth syndrome or atypical odontalgia for 12 weeks. The initial dose of duloxetine was established as 20 mg/d and was increased to 40 mg/d after week 2. We evaluated pain using the visual analog scale and depressive symptoms using the Structured Interview Guide for the Hamilton Depression Rating Scale at weeks 0, 2, 4, 6, 8, 10, and 12 and measured plasma concentrations of duloxetine 12 weeks after the start of its administration.ResultsVisual analog scale scores were significantly lower 12 weeks after than at the start of the administration of duloxetine (paired t test, t= 6.65, P< 0.0001). We examined the relationship between the rate of decreases in visual analog scale scores and plasma concentrations of duloxetine. There was no significant linear regression or quadratic regression.ConclusionsDuloxetine significantly relieved pain in patients with chronic nonorganic pain in the orofacial region. However, no relationship was observed between its pain-relieving effects and plasma concentrations.